Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response
Titel:
Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response
Auteur:
O’Dwyer, Michael E. Swords, Ronan Nagler, Arnon McMullin, Mary Frances le Coutre, Philipp D. Langabeer, Stephen E. Alvarez-Iglesias, Alberto Fan, Hongxin Woodman, Richard C. Giles, Francis J. Conneally, Eibhlin